1-[2-(4-Nitrophenyl)ethyl]piperazin-2-one → Methyl 5-nitro-2-(2-{4-[2-(4-nitrophenyl)ethyl]-3-oxopiperazin-1-yl}ethyl)benzoate
Reaktionsgleichung
[N+:1]([C:4]1[CH:9]=[CH:8][C:7]([CH2:10][CH2:11][N:12]2[CH2:17][CH2:16][NH:15][CH2:14][C:13]2=[O:18])=[CH:6][CH:5]=1)([O-:3])=[O:2].[N+:19]([C:22]1[CH:23]=[CH:24][C:25]([CH2:32][CH:33]=O)=[C:26]([CH:31]=1)[C:27]([O:29][CH3:30])=[O:28])([O-:21])=[O:20]>>[N+:19]([C:22]1[CH:23]=[CH:24][C:25]([CH2:32][CH2:33][N:15]2[CH2:16][CH2:17][N:12]([CH2:11][CH2:10][C:7]3[CH:8]=[CH:9][C:4]([N+:1]([O-:3])=[O:2])=[CH:5][CH:6]=3)[C:13](=[O:18])[CH2:14]2)=[C:26]([CH:31]=1)[C:27]([O:29][CH3:30])=[O:28])([O-:21])=[O:20]Komponenten
3
Versuchsvorschrift
The title compound was prepared from 1-[2-(4-Nitrophenyl)ethyl]piperazin-2-one and Methyl 5-nitro-2-(2-oxoethyl)benzoate following essentially the same procedure as Example 6. The product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA). LC-MS (IE, m/z): 457 [M+1]+.
Aufarbeitung
- customThe product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA)